Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders' Equity

v3.23.2
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Conversion of Convertible Debt
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Conversion of Convertible Debt
Stockholders’ Accumulated Deficit
Balance, at beginning of period at Dec. 31, 2021 $ 25,212     $ 206,776   $ (181,564)
Balance, at beginning of period (in shares) at Dec. 31, 2021     3,753,132      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options 123     123    
Exercise of stock options (in shares)     15,250      
Vesting of restricted stock units, net of taxes (108)     (108)    
Vesting of restricted stock units, net of taxes (in shares)     12,123      
Stock-based compensation expense 2,408     2,408    
Net income (loss) 24,982         24,982
Balance, at end of period at Jun. 30, 2022 52,617   $ 0 209,199   (156,582)
Balance, at end of period (in shares) at Jun. 30, 2022     3,780,505      
Balance, at beginning of period at Mar. 31, 2022 15,434   $ 0 207,754   (192,320)
Balance, at beginning of period (in shares) at Mar. 31, 2022     3,757,675      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options 117     117    
Exercise of stock options (in shares)     14,028      
Vesting of restricted stock units, net of taxes (108)     (108)    
Vesting of restricted stock units, net of taxes (in shares)     8,802      
Stock-based compensation expense 1,436     1,436    
Net income (loss) 35,738         35,738
Balance, at end of period at Jun. 30, 2022 52,617   $ 0 209,199   (156,582)
Balance, at end of period (in shares) at Jun. 30, 2022     3,780,505      
Balance, at beginning of period at Dec. 31, 2022 54,558   $ 1 220,951   (166,394)
Balance, at beginning of period (in shares) at Dec. 31, 2022     4,492,157      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options $ 10     10    
Exercise of stock options (in shares) 9,502   9,502      
Vesting of restricted stock units, net of taxes $ (14)     (14)    
Vesting of restricted stock units, net of taxes (in shares)     35,360      
Conversion of convertible notes payable 1,894 $ 8,567   1,894 $ 8,567  
Conversion of convertible notes payable (in shares)     461,548      
Canceled due to reverse split (in shares)     (1,957)      
Stock-based compensation expense 2,801     2,801    
Net income (loss) (44,883)         (44,883)
Balance, at end of period at Jun. 30, 2023 22,933   $ 1 234,209   (211,277)
Balance, at end of period (in shares) at Jun. 30, 2023     6,144,553      
Balance, at beginning of period at Mar. 31, 2023 41,137   $ 1 230,965   (189,829)
Balance, at beginning of period (in shares) at Mar. 31, 2023     5,652,448      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options 3     3    
Exercise of stock options (in shares)     2,758      
Vesting of restricted stock units, net of taxes (12)     (12)    
Vesting of restricted stock units, net of taxes (in shares)     29,756      
Conversion of convertible notes payable 1,894     1,894    
Conversion of convertible notes payable (in shares)   1,147,943 461,548      
Canceled due to reverse split (in shares)     (1,957)      
Stock-based compensation expense 1,359     1,359    
Net income (loss) (21,448)         (21,448)
Balance, at end of period at Jun. 30, 2023 $ 22,933   $ 1 $ 234,209   $ (211,277)
Balance, at end of period (in shares) at Jun. 30, 2023     6,144,553